Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06340997
Other study ID # Mitral Stenosis
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 1, 2024
Est. completion date August 1, 2027

Study information

Verified date March 2024
Source Assiut University
Contact Mohamed Ismail
Phone 01091806181
Email prep.ismail@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

• Evaluation of the effect of PTMC on LAA function by TEE at least one month after the procedure and its effectiveness in prevention of thrombi formation and cerebrovascular complications.


Description:

- Mitral stenosis (MS) is a disabling disease that limits the normal physical abilities of patients and considered as a major reason for hospital admissions . The leading cause of MS globally is rheumatic heart disease(RHD), which remains common in economically developing countries and continues to be a significant cause of morbidity and mortality. - Chronic pressure and volume overload imposed by MS causes left atrial (LA) and Left Atrial Appendage (LAA) dysfunction leading to reduced blood flow velocities thereby producing stasis of blood, reduced LA and LAA ejection fraction and atrial fibrillation (AF). - These factors predispose to formation of LA and LAA thrombi in MS and result in thromboembolic episodes. Risk of cerebrovascular accident (CVA) is increased approximately five-fold in non-rheumatic AF and 17-fold in patients with MS with AF. Even patients of MS in sinus rhythm with depressed LA and LAA function are at increased risk of CVA. Assessment of LAA function is helpful in predicting the risk of thromboembolism . - PTMC can improve the function of the LAA by reducing the left atrial pressure and increasing the blood flow through the mitral valve. - Echocardiography, particularly transesophageal echocardiography (TEE), is currently the modality of choice for evaluation of the LAA. Transesophageal echocardiography (TEE) allows semi-invasive, highly accurate imaging of the functional efficiency of LAA by LAA Doppler and Doppler tissue imaging (DTI) . - MS causes decreased LAA Doppler and DTI velocities in patients even with sinus rhythm . So, this study aims to evaluate effect of successful PTMC on LAA function by TEE Doppler and DTI (doppler tissue imaging). - Fractional area change (FAC): The FAC is a measure of the percentage of change in the area of the LAA during systole. A higher FAC indicates a more contractile LAA.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 25
Est. completion date August 1, 2027
Est. primary completion date October 1, 2026
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - • Patient eligible for PTMC as anatomical characteristics àpatient with sever MS (area 1.5cm2, echocardiographic score (Wilkins score = 8, Cormier score 1 and 2 …), contraindication or high risk to surgical MVR. Exclusion Criteria: - Patient with mitral regurgitation more than grade II . - Patient not eligible to PTMC. - Patient with severe heart failure (NHYA class IV) . - Patient with previous Cerebrovascular accident . - Patient with contraindication to TEE ( esophageal disease like stricture , diverticuli, varices, …, uncooperative patient )

Study Design


Intervention

Device:
Transesophageal echocardiography
D.Echocardiography(Transthoracic and transesophageal): 2D echocardiography (to detect LA function, severity of MS and Wilkins score). The following conventional parameters were measured : left atrial volume index (LAVi), and left ventricular ejection fraction (LVEF) by modified biplane Simpson's rule , left atrial emptying fraction calculated as (LAVi max-LAVi min)/LAVi max × 100 ,]degree of concomitant mitral regurgitation. The maximum and minimum LAA areas were measured by planimetry. LAA area change (%) was calculated using the following formula: LAA area change = [(maximal LAA area-minimal LAA area)/maximal LAA area] × 100. Transesophageal echocardiogram (TEE) (to detect LAA function) . LAA flow velocity patterns by pulsed-wave Doppler Early diastolic emptying velocity Late diastolic emptying velocity or LAA contraction flow LAA filling velocity Systolic reflection waves Two-Dimensional- LAA fractional area change (LAAAC%)

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Outcome

Type Measure Description Time frame Safety issue
Primary Impact of Percutaneous Transvenous Mitral Commissurotomy on The Left Atrial Appendage Function in Patients with Mitral Stenosis. Assessment of left atrial appendage function pre and post PTMC. This assessment will be carried out through echocardiography by describing if it contains thrombus or not. basline
Secondary Prevention of left atrial appendage thrombus. Improvement of LAA function and its clinical repercussion in preventing thrombus formation and consequently cerebrovascular accidents by follow up LAA function and whether thrombus is formed or not. basline
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06167213 - ALLIANCE Mitral: Safety and Effectiveness of SAPIEN X4 Transcatheter Heart Valve - Mitral N/A
Completed NCT02188862 - Genetic Susceptibility to Rheumatic Heart Disease in the Pacific Region N/A
Recruiting NCT04045093 - Dabigatran for Mitral Stenosis Atrial Fibrillation Phase 4
Recruiting NCT05625607 - Polish Transcatheter Transfemoral Mitral Valve-in-Valve Implantation (Mitral ViV) Registry
Not yet recruiting NCT06067815 - Assessment of Right Ventricular Function in Patients With Severe Mitral Stenosis Before and After Balloon Mitral Valvuloplasty
Completed NCT01022463 - Effect of Ivabradine on Heart Rate & Effort Tolerance in Mitral Stenosis in Sinus Rhythm Phase 3
Terminated NCT03926156 - RIvoraxaban in Mitral Stenosis Phase 3
Not yet recruiting NCT06377449 - Influence of Lung Ultrasonography on the Prognosis and Postoperative Outcomes in Cardiac Surgical Patients N/A
Recruiting NCT04408430 - The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves). N/A
Active, not recruiting NCT06191718 - Clinical Investigation for the Foldax Tria Mitral Valve- India N/A
Recruiting NCT03991910 - The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients Phase 3
Completed NCT02783248 - French National Observatory of Percutaneous Mitral Commissurotomy
Recruiting NCT05925335 - The China Mviv Registry N/A
Completed NCT02502448 - Acute Normovolemic Hemodilution on ROTEM in Cardiac Surgery N/A
Completed NCT04527367 - Epidemiology and Long-term Outcome of Patients With VHD
Recruiting NCT05526560 - Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve
Completed NCT06371222 - Role of Ivabradine on Heart Rate and Quality of Life in Patients With Mitral Stenosis in Sinus Rhythm Phase 4
Completed NCT02831270 - Acute Normovolemic Hemodilution on Serum-creatinine Concentration in Cardiac Surgery N/A
Recruiting NCT01270750 - Bosentan for Severe Mitral Valve Dysfunction Phase 1/Phase 2
Active, not recruiting NCT01757665 - ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform (COMMENCE) N/A